000 03977cam a2200793Ma 4500
001 ocn797824835
003 OCoLC
005 20230823095102.0
006 m o d
007 cr cn|||||||||
008 111004s2012 njuad o 001 0 eng d
010 _z 2011041435
040 _aE7B
_beng
_epn
_cE7B
_dOCLCO
_dGPM
_dOCLCQ
_dYDXCP
_dDG1
_dOCLCF
_dNLE
_dEBLCP
_dMHW
_dN$T
_dDEBSZ
_dTEFOD
_dOCLCQ
_dCOO
_dOCLCQ
_dDEBBG
_dAZK
019 _a787842613
_a795795378
_a860353077
_a961535840
_a962593706
020 _a9781118266793
_q(e-book)
020 _a111826679X
_q(e-book)
020 _a9781118266755
_q(electronic bk.)
020 _a1118266757
_q(electronic bk.)
020 _a9781118265895
020 _a1118265890
020 _z9780470487532
_q(cloth)
029 1 _aAU@
_b000049595452
029 1 _aAU@
_b000052892862
029 1 _aDEBBG
_bBV040819099
029 1 _aDEBBG
_bBV042744068
029 1 _aDEBSZ
_b397219334
029 1 _aDEBSZ
_b425884864
029 1 _aDEBSZ
_b431081964
029 1 _aDEBSZ
_b449279715
029 1 _aDKDLA
_b820120-katalog:000599538
029 1 _aGBVCP
_b790037688
029 1 _aNLGGC
_b389383082
029 1 _aNZ1
_b14976381
029 1 _aDEBBG
_bBV043394631
035 _a(OCoLC)797824835
_z(OCoLC)787842613
_z(OCoLC)795795378
_z(OCoLC)860353077
_z(OCoLC)961535840
_z(OCoLC)962593706
037 _a10.1002/9781118266755
_bWiley InterScience
_nhttp://www3.interscience.wiley.com
037 _a3DFCF16A-0556-4E88-9BD9-2DD2607838E2
_bOverDrive, Inc.
_nhttp://www.overdrive.com
050 4 _aHD9666.5
_b.E45 2012eb
060 4 _aQV 736
072 7 _aBUS
_x070080
_2bisacsh
082 0 4 _a338.4/76153
_223
049 _aMAIN
100 1 _aEllery, Tony.
245 1 0 _aPharmaceutical lifecycle management :
_bmaking the most of each and every brand /
_cTony Ellery, Neal Hansen.
260 _aHoboken, N.J. :
_bJohn Wiley & Sons,
_c©2012.
300 _a1 online resource (xxii, 389 pages :) :
_billustrations
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _adata file
_2rda
500 _aIncludes index.
505 0 _apt. A. Lifecycle management business environment -- pt. B. Lifecycle management regulatory and legal environment -- pt. C. Patents and exclusivities -- pt. D. Developmental LCM -- pt. E. Commercial LCM -- pt. F. Biologics and biosimilars -- pt. G. The integrated brand LCM strategy and its implementation -- pt. H. Integrating LCM with portfolio management.
520 _aA comprehensive guide to optimizing the lifecycle management of pharmaceutical brandsThe mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they can--and must--do to get.
650 0 _aPharmaceutical industry
_xEconomic aspects.
650 0 _aDrug approval
_xEconomic aspects.
650 1 2 _aDrug Industry
_xeconomics.
650 2 2 _aDrug Approval
_xeconomics.
650 2 2 _aEconomics, Pharmaceutical
_xlegislation & jurisprudence.
650 2 2 _aMarketing
_xmethods.
650 2 2 _aPharmaceutical Preparations
_xeconomics.
650 7 _aBUSINESS & ECONOMICS
_xIndustries
_xService.
_2bisacsh
650 7 _aPharmaceutical industry.
_2fast
_0(OCoLC)fst01060129
655 4 _aElectronic books.
700 1 _aHansen, Neal.
776 0 8 _iPrint version:
_aEllery, Tony.
_tPharmaceutical lifecycle management.
_dHoboken, N.J. : John Wiley & Sons, ©2012
_z9780470487532
_w(DLC) 2011041435
_w(OCoLC)756895018
856 4 0 _uhttp://dx.doi.org/10.1002/9781118266755
_zWiley Online Library
994 _a92
_bDG1
999 _c19552
_d19511
526 _bmkt